Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
86 stopped studies mapped to Myelodysplastic/Myeloproliferative Neoplasm and descendants · 91% state a reason
Over the 86 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06071624 | Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line… | Phase 1 | suspended | Oct 6, 2023 | Huda Salman | Trial being transferred to new lead site | Other (stated, no rule matched) |
| NCT06597734 | A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in… | Phase 2 | withdrawn | Sep 19, 2024 | M.D. Anderson Cancer Center | PI request | Other (stated, no rule matched) |
| NCT06680661 | ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis | Phase 2 | suspended | Nov 8, 2024 | Leland Metheny | insufficient funding | Funding |
| NCT03146871 | Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or… | Phase 2 | terminated | May 10, 2017 | University of Southern California | Lack of funding | Funding |
| NCT04550442 | Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk… | Phase 1 / Phase 2 | terminated | Sep 16, 2020 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06630221 | Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations | Phase 2 | suspended | Oct 8, 2024 | Abhay Singh, MD MPH | Funding unavailable | Funding |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity… | Phase 2 | terminated | Aug 11, 2017 | Fred Hutchinson Cancer Center | Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and… | Safety / toxicity |
| NCT06563804 | A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in… | Phase 1 / Phase 2 | terminated | Aug 21, 2024 | Servier Bio-Innovation LLC | Sponsor decision | Sponsor / business decision |
| NCT03922100 | Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML | Phase 1 / Phase 2 | terminated | Apr 19, 2019 | Nerviano Medical Sciences | Study stopped due to strategic reasons. The decision is not based on specific safety findings as… | Safety / toxicity |
| NCT04953312 | Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)(CALPRO) | N/A | withdrawn | Jul 7, 2021 | Assistance Publique - Hôpitaux de Paris | Abandonment of the study project | Other (stated, no rule matched) |
| NCT03404193 | Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid… | Phase 2 | terminated | Jan 19, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04160052 | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory… | Phase 1 / Phase 2 | terminated | Nov 12, 2019 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04937166 | A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological… | Phase 1 | terminated | Jun 23, 2021 | Kahr Medical | Slow enrolment | Enrollment / accrual |
| NCT05209152 | AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic… | Phase 1 | terminated | Jan 26, 2022 | Amgen | Sponsor decision, unrelated to safety | Safety / toxicity |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell… | Phase 2 | terminated | Nov 7, 2017 | Roswell Park Cancer Institute | Futility analysis determined closure | Efficacy / futility |
| NCT04752163 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of… | Phase 1 / Phase 2 | terminated | Feb 12, 2021 | M.D. Anderson Cancer Center | supporting/funding source decided to de-prioritize and stop development of DS-1594 | Funding |
| NCT05005182 | Luspatercept With or Without Hydroxyurea for the Treatment of… | Phase 2 | terminated | Aug 13, 2021 | Mayo Clinic | Slow accrual | Enrollment / accrual |
| NCT04637009 | A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)… | Phase 1 | terminated | Nov 19, 2020 | Astex Pharmaceuticals, Inc. | termination due to portfolio prioritization | Sponsor / business decision |
| NCT05895201 | High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the… | Phase 1 / Phase 2 | withdrawn | Jun 8, 2023 | Indiana University | PI has left IU with no plan to initiate study at IU | Other (stated, no rule matched) |
| NCT06085638 | Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax… | Phase 1 / Phase 2 | withdrawn | Oct 17, 2023 | M.D. Anderson Cancer Center | Zero participants accrued | Enrollment / accrual |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or… | Phase 1 | terminated | Nov 4, 2021 | Prelude Therapeutics | Company Decision | Sponsor / business decision |
| NCT05456269 | A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With…(BISECT) | Phase 1 | withdrawn | Jul 13, 2022 | Racura Oncology Ltd | commercial reason | Other (stated, no rule matched) |
| NCT00589316 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body… | Phase 1 | terminated | Jan 9, 2008 | Fred Hutchinson Cancer Center | Terminated due to loss of funding | Funding |
| NCT00119366 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and… | Phase 2 | terminated | Jul 13, 2005 | Fred Hutchinson Cancer Center | Funding ended before target accrual was reached; participants are no longer being examined or… | Enrollment / accrual |
| NCT05246384 | Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in… | Phase 1 / Phase 2 | withdrawn | Feb 18, 2022 | Rhizen Pharmaceuticals SA | Change in development plan | Other (stated, no rule matched) |
| NCT01773395 | GVAX vs. Placebo for MDS/AML After Allo HSCT | Phase 2 | terminated | Jan 23, 2013 | Dana-Farber Cancer Institute | Recommendation by the Data and Safety Monitoring Board due to efficacy concerns | Safety / toxicity |
| NCT03519984 | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With… | Phase 1 | terminated | May 9, 2018 | University of Southern California | Study drug supply issue | Drug supply |
| NCT01620216 | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic… | Phase 2 | terminated | Jun 15, 2012 | OHSU Knight Cancer Institute | Unable to recruit enough eligible subjects | Enrollment / accrual |
| NCT00900120 | Collecting and Storing Blood Samples From Patients With Cancer | — | withdrawn | May 12, 2009 | University of Medicine and Dentistry of New Jersey | Will be replaced by honest broker program | Other (stated, no rule matched) |
| NCT04217720 | SNS-301 Monotherapy in High Risk MDS and CMML | Phase 2 | withdrawn | Jan 3, 2020 | Sensei Biotherapeutics, Inc. | Sponsor decision | Sponsor / business decision |
| NCT03602898 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate… | Phase 2 | withdrawn | Jul 27, 2018 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT00176930 | Stem Cell Transplant for Hematological Malignancy | N/A | terminated | Sep 15, 2005 | Masonic Cancer Center, University of Minnesota | replaced by another study ; Trial re-written as MT2015-29 | Other (stated, no rule matched) |
| NCT00020969 | Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes | Phase 2 | terminated | Jan 27, 2003 | CTI BioPharma | not stated | Not stated |
| NCT00726830 | Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer | N/A | terminated | Aug 1, 2008 | M.D. Anderson Cancer Center | Low Accrual. | Enrollment / accrual |
| NCT03807063 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood… | Phase 1 | withdrawn | Jan 16, 2019 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT01010256 | The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic… | — | terminated | Nov 9, 2009 | University of Arkansas | PI moved institutions | Other (stated, no rule matched) |
| NCT00085449 | Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate… | Phase 1 / Phase 2 | withdrawn | Jun 11, 2004 | Alliance for Clinical Trials in Oncology | Funding cut, no patients enrolled | Enrollment / accrual |
| NCT00651716 | T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem… | — | terminated | Apr 3, 2008 | Vanderbilt-Ingram Cancer Center | Funding unavailable | Funding |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT02749708 | Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk… | Phase 1 | terminated | Apr 25, 2016 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Study drug supply expired and could not be renewed. | Drug supply |
| NCT01116232 | Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease… | Phase 2 | terminated | May 4, 2010 | Barbara Ann Karmanos Cancer Institute | Lack of funding. | Funding |
| NCT02418000 | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or… | Phase 1 / Phase 2 | terminated | Apr 16, 2015 | Spirita Oncology, LLC | Insufficient efficacy in Phase 1 dose-escalation portion of study | Efficacy / futility |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer,… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00104806 | Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With… | Phase 2 | terminated | Mar 4, 2005 | Wake Forest University Health Sciences | sponsor discontinues support | Other (stated, no rule matched) |
| NCT00852709 | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated…(POE07-01) | Phase 1 | terminated | Feb 27, 2009 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Lack of accrual | Enrollment / accrual |
| NCT00290628 | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | N/A | terminated | Feb 13, 2006 | Masonic Cancer Center, University of Minnesota | Replaced with another study | Other (stated, no rule matched) |
| NCT00281879 | Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With… | Phase 2 | terminated | Jan 25, 2006 | OHSU Knight Cancer Institute | not stated | Not stated |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A… | N/A | terminated | Feb 26, 2010 | Fred Hutchinson Cancer Center | Funding withdrawal | Funding |
| NCT00719849 | Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological… | Phase 2 | terminated | Jul 22, 2008 | Fred Hutchinson Cancer Center | A new protocol was developed to replace this protocol in 2008, with removal of ATG and extension of… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials